Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  NASDAQ OMX COPENHAGEN  >  Coloplast A/S    COLO B   DK0060448595

COLOPLAST A/S (COLO B)

Delayed Quote. Delayed  - 09/26 12:12:37 pm
514 DKK   -0.10%
09/21 COLOPLAST A/S : delivers 9M result in line with guidance
09/15 COLOPLAST A/S : New flexible catheter part of Coloplast growth plan
09/12 COLOPLAST A/S : Insider tradings - Trading in shares
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 
The feature you requested does not exist. However, we suggest the following feature:

Coloplast A/S : delivers 9M result in line with guidance

share with twitter share with LinkedIn share with facebook
share via e-mail
0
09/21/2016 | 01:19am CEST

(GlobeNewswire) - Revenue grew by 7% organically to DKK 10,942 million in the 9M 2015/16 period. EBIT was up by 8% to DKK 3,562 million for an EBIT margin of 33%. The results are in line with expectations.

All over the world, more and more people living with a stoma are choosing Coloplasts stoma bags and accessories. As a result, the companys sales outperformed the market in the first nine months of the financial year. Sales in the Ostomy Care business area grew by 11% in the third quarter and by 9% in the 9M reporting period.

- Our latest ostomy care product, the SenSura Mio Convex is now available in sixteen countries, and feedback from users and healthcare professionals remains highly satisfactory. We now have the complete SenSura Mio portfolio on the market, which has a positive effect on growth in our Ostomy Care business, says Coloplast CEO Lars Rasmussen.

Sales in the Continence Care business grew 5% in the 9M period, mainly driven by disposable Speedicath catheters and Peristeen. Sales in the US market remain challenged as distributors continue to downscale their inventories, but the underlying growth is positive.

The Wound & Skin Care business delivered 7% organic growth. The European market is a positive contributor, while the Wound Care business remains challenged by slowing growth in China. Urology Care sales were up by a satisfactory 8%.

Solid growth in Europe

Coloplasts sales to the European market were up by 6% in the 9M reporting period and by 8% in the third quarter alone, in part driven by solid growth in the UK market.

- With the UK being our largest single market, Im very pleased to note that we are again generating strong growth in the UK and that users are happy with our products. Were winning market share, and thats very satisfactory, Lars Rasmussen says.

Germany and the Nordic markets also contributed to sales growth. In non-European markets, Argentina, China and Russia were the main contributors.

Maintaining guidance

Coloplast maintains its guidance for the 2015/2016 financial year of 78% organic revenue growth at constant exchange rates and now of about 6% in DKK. The EBIT margin is expected to be 3334% at constant exchange rates and about 33% in DKK.

For more on the Q3 2015/16 interim report, go to www.coloplast.com/investor.

Press enquiriesMaria LindebergSenior Media Relations ManagerTel. +45 4911 3095dkmalg@coloplast.com

Investors and analystsEllen BjurgertInvestor Relations ManagerTel. +45 4911 3376dkebj@coloplast.com

(c) All rights reserved The Jerusalem Post 1995 - 2016 Provided by SyndiGate Media Inc. (Syndigate.info)., source Middle East & North African Newspapers

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on COLOPLAST A/S
09/21 COLOPLAST A/S : delivers 9M result in line with guidance
09/15 COLOPLAST A/S : New flexible catheter part of Coloplast growth plan
09/12 COLOPLAST A/S : Insider tradings - Trading in shares
09/09 COLOPLAST A/S : Patent Issued for Method for Rounding Edges of Openings in a Tub..
09/02 COLOPLAST A/S : Insider tradings - Exercise of share options
09/01 COLOPLAST A/S : Patent Issued for Implantable Support with Dilator Attached to A..
08/18 COLOPLAST A/S : Patent Issued for Method of Treating Peyronie'S Disease (USPTO 9..
08/16 COLOPLAST A/S : delivers 9M result in line with guidance
08/16 COLOPLAST A/S : Share buy-back
08/11COLOPLAST A/S : quaterly earnings release
More news
Sector news : Medical Equipment Wholesale
09/17DJJ&J to Buy Abbott Eye Business -- WSJ
09/16DJJ&J to Buy Abbott's Eye-Surgery Unit for $4.325 billion -- 2nd Update
09/16DJJ&J to Buy Abbott's Eye-Surgery Unit for $4.325 billion -- 3rd Update
09/16DJJ&J to Buy Abbott's Eye-Surgery Unit for $4.325 billion -- Update
09/16DJJ&J Nears Deal to buy Abbott's Eye-Surgery Equipment Unit
More sector news : Medical Equipment Wholesale
News from SeekingAlpha
07/06 Sun Comes Out For Big-Cap Medtechs As Investors Seek Refuge From Market Squal..
07/03 These stocks should generate superior ROE and FCF - Barclays
2015 GIVING UP A HOBBY : Putting My Portfolio On Autopilot
2015 THE GLOBAL X FTSE NORDIC REGION ETF : The Perfect Fit
2015 Coloplast Is A Rare Story On Multiple Levels
Advertisement
Financials ( DKK)
Sales 2016 14 766 M
EBIT 2016 4 869 M
Net income 2016 3 711 M
Finance 2016 313 M
Yield 2016 2,68%
P/E ratio 2016 29,31
P/E ratio 2017 26,55
EV / Sales 2016 6,88x
EV / Sales 2017 6,42x
Capitalization 101 871 M
More Financials
Chart COLOPLAST A/S
Duration : Period :
Coloplast A/S Technical Analysis Chart | COLO B | DK0060448595 | 4-Traders
Full-screen chart
Technical analysis trends COLOPLAST A/S
Short TermMid-TermLong Term
TrendsNeutralBullishNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 21
Average target price 524  DKK
Spread / Average Target 1,8%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Lars Søren Rasmussen President & Chief Executive Officer
Michael Pram Rasmussen Chairman
Allan Rasmussen Executive Vice President-Global Operations
Anders Lonning-Skovgaard CFO, EVP & Head-Investor Relations
Oliver Johansen Senior VP-Global Research & Development
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
COLOPLAST A/S-6.73%15 359
HENRY SCHEIN, INC.3.96%13 451
PATTERSON COMPANIES, I..3.25%4 630
AMPLIFON SPA13.57%2 303
OWENS & MINOR, INC.-4.36%2 147
SHIP HEALTHCARE HOLDIN..-1.13%1 536
More Results